To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase
II/III clinical trial. It will be conducted at selected investigational sites globally. The
study is comprised of 2 parts.